NEOGEN CORP (NEOG)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for NEOG
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NEOG | Nominee; Executive Chairman | ["Global diagnostics executive with over 25 years of experience", "Executive Chairman at JointMedica", "Senior Advisor at TPG", "Former CEO, President, and Director of Immucor (2018\u20132023)", "Led turnaround and $2 billion sale to Werfen", "Global President of Infectious Disease at Alere (2007\u20132017)", "Built a $750 million global portfolio", "Launched first FDA CLIA-Waived point-of-care molecular test", "Held leadership roles at Chembio Diagnostics Systems", "Began career at Citibank in Latin America capital markets"] | [] | 2025 |
Biography sourced from the proxy statement filing.
On August 14, 2025, Avi Pelossof was appointed to the Board, effective October 24, 2025. A global diagnostics executive with over 25 years of experience, Mr. Pelossof is currently Executive Chairman at JointMedica and Senior Advisor at TPG. He previously served as CEO, President, and Director of Immucor (2018 2023), leading its turnaround and $2 billion sale to Werfen. Before that, he was Global President of Infectious Disease at Alere (2007 2017), where he built the business into a $750 million global portfolio and launched the first FDA CLIA-Waived point-of-care molecular test, later rebranded by Abbott as ID NOW. Earlier, Mr. Pelossof held leadership roles at Chembio Diagnostics Systems and began his career at Citibank in Latin America capital markets.